Monoclonal Antibody News and Research

RSS

Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

NJIT researchers develop new efficient method for targeted protein analysis

Researchers at New Jersey Institute of Technology in collaboration with Ohio University and Merck & Co. Inc. recently developed a new efficient method for targeted protein analysis -- one they say could speed up processes for disease testing, drug discovery and vaccine development.

17 Jun 2020

An improved tetravalent antibody blocks SARS-CoV-2 infection

A new study published on the preprint server bioRxiv* in June 2020 shows the potential of a new fusion molecule called a biparatopic protein to inhibit viral interaction with the host cell ACE2 receptor. This could lead to therapeutic applications.

17 Jun 2020

Antibody cocktail with potential to treat COVID-19 identified

Researchers at the University of Maryland School of Medicine (UMSOM) evaluated several human antibodies to determine the most potent combination to be mixed in a cocktail and used as a promising anti-viral therapy against the virus that causes COVID-19.

16 Jun 2020

Romosozumab offers considerable added benefit for postmenopausal women with osteoporosis

Romosozumab is a bone-forming monoclonal antibody used in women after menopause for the treatment of severe osteoporosis if there is a high risk of bone fractures.

15 Jun 2020

Progression and severity of COVID-19 highly dependant on cytokine changes

A new review paper by the researchers from Spain, published in the journal Cytokine & Growth Factor Reviews, demonstrates how changes in the levels of cytokines and other biomolecules are associated with the presence and more serious prognosis of coronavirus disease (COVID-19).

11 Jun 2020

Novel compound shows promise for ANCA-associated vasculitis

ANCA-associated vasculitis (AAV) is a systemic disease involving the formation of special autoantibodies (so-called anti-neutrophil cytoplasmic antibodies/ANCA) and vascular inflammation.

8 Jun 2020

AFFiRiS announces preclinical results of monoclonal antibody mAB C6-17 in Huntington's

AFFiRiS, a clinical-stage biotechnology company developing novel disease-modifying specific active immunotherapies, today announced that detailed preclinical results with its monoclonal antibody mAB C6-17 to treat Huntington's Disease were published in the peer-reviewed journal Neurobiology of Disease.

3 Jun 2020

Monoclonal antibody therapy achieves modest reduction in recurrence for patients with HER2-positive DCIS

The addition of the monoclonal antibody therapy Trastuzumab to radiotherapy did not reach the protocol objective of a 36% reduction in the ipsilateral breast tumor recurrence rate for women with HER2-positive ductal carcinoma in situ (DCIS) on the NRG Oncology clinical trial NSABP B-43.

29 May 2020

Addition of monoclonal antibody to trimodality therapy offers no benefit in HER2 over expressing esophageal cancer

Results of the NRG Oncology clinical trial RTOG 1010 indicated that the addition of the monoclonal antibody trastuzumab to neoadjuvant trimodality treatment did not improve disease-free survival outcomes for patient with HER2 overexpressing local and locally advanced esophageal adenocarcinoma.

29 May 2020

Measuring the binding of SARS-CoV-2 antibodies to the COVID spike protein using SPR

Ryan Denomme, the CEO of Nicoya, speaks to News-Medical on their SARS-CoV-2 research using their SPR technology.

From Nicoya Lifesciences 28 May 2020

The use of rheumatoid arthritis drug sarilumab in severe COVID-19 pneumonia

A new study published on the preprint server medRxiv* in May 2020 reports the beneficial effects of the monoclonal antibody sarilumab in severe COVID-19 pneumonia.

19 May 2020

Innovent Biologics and MD Anderson to develop sintilimab injection for rare cancers

The University of Texas MD Anderson Cancer Center and Innovent Biologics, Inc. today announced a strategic collaboration agreement to co-develop TYVYT® (sintilimab injection), Innovent's anti-PD-1 monoclonal antibody, in rare cancers in the U. S...

19 May 2020

Human immune repertoire may not commonly produce cross-neutralizing antibodies to coronaviruses

Patients infected with either severe acute respiratory syndrome coronavirus (SARS-CoV) or SARS-CoV-2 produce antibodies that bind to the other coronavirus, but the cross-reactive antibodies are not cross protective, at least in cell-culture experiments, researchers report May 17 in the journal Cell Reports.

18 May 2020

Cross-neutralization of SARS and COVID-19 coronaviruses by a monoclonal antibody

An antibody first identified in a blood sample from a patient who recovered from Severe Acute Respiratory Syndrome in 2003 inhibits related coronaviruses, including the cause of COVID-19.

18 May 2020

Takeda to present oncology pipeline data at upcoming virtual scientific congresses

Takeda Pharmaceutical Company Limited today announced that the company will present data from its expanding oncology pipeline and established product portfolio at two upcoming virtual scientific congresses: the 56th Annual Meeting of the American Society of Clinical Oncology, May 29-31 and the 25th Virtual Congress of the European Hematology Association, June 11-14.

18 May 2020

Study shows human monoclonal antibodies can effectively neutralize SARS-CoV-2

US researchers have published a proof of concept on the efficacy of human monoclonal antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in laboratory conditions, as well as their pioneering use in a mouse model. The study is available on the preprint server bioRxiv*.

17 May 2020

Chasing the elusive dream of a COVID cure

Although scientists and stock markets have celebrated the approval for emergency use of remdesivir to treat COVID-19, a cure for the disease that has killed nearly 260,000 people remains a long way off — and might never arrive.

15 May 2020

HVTN and HPTN initiate first clinical trial in response to COVID-19

The NIH-funded HIV Vaccine Trials Network (HVTN) and HIV Prevention Trials Network (HPTN) have initiated their first clinical trial in response to COVID-19.

15 May 2020

Varied performance of SARS-CoV-2 antibody tests in detecting protective immunity

The performance of commercially available serological tests in real patient samples and the correlates of immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) provided by IgG antibodies are still a matter of debate. A new bioRxiv preprint paper cross-examines the performance of several assays and proclaims the plaque reduction neutralization test (PRNT) as a method of choice.

11 May 2020

COVID survivors’ blood plasma is a sought-after new commodity

Diana Berrent learned she had tested positive for COVID-19 on a Wednesday in mid-March. Within a day, she had received 30 emails from people urging her to donate blood.

11 May 2020

Monoclonal Antibody News and Research

Further Reading

NJIT researchers develop new efficient method for targeted protein analysis

An improved tetravalent antibody blocks SARS-CoV-2 infection

Antibody cocktail with potential to treat COVID-19 identified

Romosozumab offers considerable added benefit for postmenopausal women with osteoporosis

Progression and severity of COVID-19 highly dependant on cytokine changes

Novel compound shows promise for ANCA-associated vasculitis

AFFiRiS announces preclinical results of monoclonal antibody mAB C6-17 in Huntington's

Monoclonal antibody therapy achieves modest reduction in recurrence for patients with HER2-positive DCIS

Addition of monoclonal antibody to trimodality therapy offers no benefit in HER2 over expressing esophageal cancer

Measuring the binding of SARS-CoV-2 antibodies to the COVID spike protein using SPR

The use of rheumatoid arthritis drug sarilumab in severe COVID-19 pneumonia

Innovent Biologics and MD Anderson to develop sintilimab injection for rare cancers

Human immune repertoire may not commonly produce cross-neutralizing antibodies to coronaviruses

Cross-neutralization of SARS and COVID-19 coronaviruses by a monoclonal antibody

Takeda to present oncology pipeline data at upcoming virtual scientific congresses

Study shows human monoclonal antibodies can effectively neutralize SARS-CoV-2

Chasing the elusive dream of a COVID cure

HVTN and HPTN initiate first clinical trial in response to COVID-19

Varied performance of SARS-CoV-2 antibody tests in detecting protective immunity

COVID survivors’ blood plasma is a sought-after new commodity

Antibodies eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®